AI assistant
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2023
Feb 17, 2023
31542_dirs_2023-02-17_a4b4728c-7a9d-4157-8484-4a3df62256fd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2023-02-15
Reporting Person: Del Carmen Jeffrey (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-15 | Common stock, par value $0.001 per share | M | 10666 | — | Acquired | 10666 | Direct |
| 2023-02-15 | Common stock, par value $0.001 per share | F | 3125 | — | Disposed | 7541 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-15 | Restricted Stock Units | $ | M | 10666 | Disposed | Common Stock (10666) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units.
F3: Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025.
F4: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on February 15, 2023.